TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27261993

Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Yoga and Exercise
Number of subjects: 88
Study: 24238984

Group type: EXPERIMENTAL
Intervention: Helmet therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: No helmet therapy (control)
Number of subjects: 128
Study: 22441566

Group type: EXPERIMENTAL
Intervention: Cetuximab-based treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bevacizumab-based treatment
Number of subjects: 54
Study: 20008831

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly for 13 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17413113

Group type: EXPERIMENTAL
Intervention: Vegetable group (5.6 mg beta-carotene/d from green leafy vegetables)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Fruit group (4.8 mg beta-carotene/d from orange or yellow fruit)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Retinol-rich group (610 microg retinol/d from animal foods and 0.6 mg beta-carotene/d)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (0.4 mg beta-carotene/d)
Number of subjects: 280
Study: 17324333

Group type: EXPERIMENTAL
Intervention: Bortezomib with pegylated liposomal doxorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib without pegylated liposomal doxorubicin
Number of subjects: 0
Study: 15672797

Group type: COMPARATOR
Intervention: Conventional oxygenator
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxygenator with venous-arterial shunt
Number of subjects: 20
Study: 11115437

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) DPI 400 microg bid
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) DPI 800 microg bid
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral prednisone 10 mg qd
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) MDI 800 microg bid
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 880 microg bid
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mometasone furoate (MF) MDI 400 microg bid
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9363727

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (800 mg/day for 12 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1543782

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis fluid (2.0 L)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No peritoneal dialysis fluid
Number of subjects: 11
Study: 3991126

Group type: EXPERIMENTAL
Intervention: UV-filtering intraocular lens (IOL)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Non-UV-filtering intraocular lens (IOL)
Number of subjects: 301
Study: 31569208

Group type: EXPERIMENTAL
Intervention: Health-related claims made by alcohol marketers and producers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol products marketed as healthier options
Number of subjects: 0
Study: 28660740

Group type: EXPERIMENTAL
Intervention: PEG-asparaginase (Oncaspar®) 1,000 IU/m²/dose, administered biweekly
Number of subjects: 97
Study: 26262196

Group type: EXPERIMENTAL
Intervention: Mobile app follow-up care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional in-person follow-up care
Number of subjects: 0
Study: 23782504

Group type: EXPERIMENTAL
Intervention: Action 3:30 PA intervention delivered by trained teaching assistants (TAs) including a 25-hour training program, first-aid certification, ongoing support, and 40 one-hour session plans for 20 weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Action 3:30 PA intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Qualitative assessments at the end of the intervention period
Number of subjects: 20

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 20
Study: 21171937

Group type: EXPERIMENTAL
Intervention: Testosterone (250 mg of testosterone enanthate every 4 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 52
Study: 18053317

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Simvastatin (10-80 mg)
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-80 mg)
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Ezetimibe and statins (co-administration)
Number of subjects: 975

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 975
Study: 17175680

Group type: EXPERIMENTAL
Intervention: Tailored self-management (TSM)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Computer-aided enhanced usual care (UC)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: TSM
Number of subjects: 335
Study: 12625376

Group type: EXPERIMENTAL
Intervention: DDAT exercise programme used daily at home
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (same treatment at school, no DDAT exercise programme)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: DDAT exercise programme
Number of subjects: 35
Study: 10741262

Group type: EXPERIMENTAL
Intervention: Oftan-dipivefrin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glaucon
Number of subjects: 60
Study: 8601979

Group type: EXPERIMENTAL
Intervention: Bair Hugger system (3 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electric blanket (4 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Space blanket
Number of subjects: 0
Study: 1528786

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) 25 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) 50 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) 70 mg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3907791

Group type: COMPARATOR
Intervention: Succinylcholine 1 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atracurium 400 micrograms/kg
Number of subjects: 40
Study: 30420478

Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate (DAmB)
Number of subjects: 78
Study: 29751746

Group type: EXPERIMENTAL
Intervention: Health Factors (HF) indicating current tobacco use
Number of subjects: 1713
Study: 26450534

Group type: EXPERIMENTAL
Intervention: Target systolic blood pressure <150 mm Hg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Target systolic blood pressure <180 mm Hg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study: 24505200

Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination (BTFC)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 58
Study: 22545212

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) applied daily on vastus lateralis, vastus medialis, and peroneus longus of both lower extremities.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Handgrip strength assessment
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (no EMS)
Number of subjects: 142
Study: 21125816

Group type: EXPERIMENTAL
Intervention: 1 mg entecavir dispersible tablets under fasted conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1 mg entecavir dispersible tablets under fed conditions
Number of subjects: 12
Study: 17692717

Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 10 mg
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 20 mg
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Oxycodone IR 15 mg
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 15119915

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.d.
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study: 11317600

Group type: EXPERIMENTAL
Intervention: Dental health education program (four one-hour lessons)
Number of subjects: 32
Study: 9444883

Group type: EXPERIMENTAL
Intervention: Preliminary data showing 9 out of 10 patients improved with drug A
Number of subjects: 165

Group type: COMPARATOR
Intervention: Preliminary data showing 5 out of 10 patients improved with drug B
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Higher P values presented to subjects
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Smaller differences in effectiveness presented to subjects
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 165
Study: 8278066

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 22
Study: 3114794

Group type: COMPARATOR
Intervention: Nicotine gum (0 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicotine gum (8 mg)
Number of subjects: 8
Study: 30891903

Group type: EXPERIMENTAL
Intervention: Step-by-step teaching method
Number of subjects: 40

Group type: COMPARATOR
Intervention: All-in-one teaching method (control group)
Number of subjects: 40
Study: 29683810

Group type: EXPERIMENTAL
Intervention: High-intensity physical activity (PA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) preconditioning
Number of subjects: 12
Study: 27163830

Group type: EXPERIMENTAL
Intervention: Transdermal 17β-estradiol (50μg/day)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: COMPARATOR
Intervention: Oral CEE (0.45 mg/day)
Number of subjects: 118
Study: 25183926

Group type: COMPARATOR
Intervention: Levobupivacaine with 1ml of isotonic saline (Group L)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine with 1ml of (100 microgram) dexmedetomidine (Group LD)
Number of subjects: 60
Study: 22459748

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (intermittent walking to nearly maximal claudication pain, 3 days per week)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 142
Study: 21143443

Group type: EXPERIMENTAL
Intervention: Leg power
Number of subjects: 116
Study: 17647003

Group type: EXPERIMENTAL
Intervention: CCR5 inhibitor SCH351125
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15833572

Group type: EXPERIMENTAL
Intervention: Web-form survey (n=137)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Paper-form survey (n=143)
Number of subjects: 280
Study: 12199726

Group type: EXPERIMENTAL
Intervention: PNESs alone (n=50)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Healthy controls (n=50)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: PNESs alone (n=130)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: PNES+E (n=57)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: PNES-only (n=130)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Both groups (PNESs and controls)
Number of subjects: 187
Study: 10480473

Group type: EXPERIMENTAL
Intervention: Irbesartan plus HCTZ (various combinations)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Irbesartan monotherapy (0, 37.5, 100, and 300 mg)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: HCTZ monotherapy (0, 6.25, 12.5, and 25 mg)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 683
Study: 8836471

Group type: EXPERIMENTAL
Intervention: Sexual words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Romantic words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Word familiarity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Word emotionality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Word acceptability
Number of subjects: 0
Study: 1747725

Group type: EXPERIMENTAL
Intervention: Low dose alpha-2b interferon (10 x 10(6) IU)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High dose alpha-2b interferon (100 x 10(6) IU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ethoglucid
Number of subjects: 44
Study: 6758093

Group type: EXPERIMENTAL
Intervention: Factor XIII (Fibrogammine)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30278459

Group type: EXPERIMENTAL
Intervention: B&B Bubbler©
Number of subjects: 43

Group type: COMPARATOR
Intervention: BabiPlus©
Number of subjects: 43

Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 43
Study: 27307305

Group type: EXPERIMENTAL
Intervention: broad-spectrum antibiotics (ciprofloxacin, vancomycin and metronidazole) for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: broad-spectrum antibiotics
Number of subjects: 16
Study: 26308780

Group type: EXPERIMENTAL
Intervention: Mobile health intervention for medication adherence and blood pressure control (3-month duration)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard-care group (control)
Number of subjects: 19
Study: 24436453

Group type: EXPERIMENTAL
Intervention: Vaginally applied tenofovir gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22520693

Group type: EXPERIMENTAL
Intervention: Platelet function analysis using thrombelastography
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 51
Study: 19023644

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MTP) 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Triamcinolone (TMC) 40 mg
Number of subjects: 24
Study: 17369514

Group type: EXPERIMENTAL
Intervention: Knowledge of Performance (KP) feedback, focusing on arm joint movements
Number of subjects: 28

Group type: COMPARATOR
Intervention: Knowledge of Results (KR) feedback, focusing on movement precision
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nondisabled control group (n = 5) practicing the same task with KR
Number of subjects: 28
Study: 15138948

Group type: EXPERIMENTAL
Intervention: Intervention hospitals with multiple dissemination strategies for the Ottawa Ankle Rules (OARs)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intervention hospitals with sequential directed education and personalized feedback strategies
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 4
Study: 10867040

Group type: EXPERIMENTAL
Intervention: 5.0 g/d HPMC in 240 mL of orange drink taken between meals
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 5.0 g/d HPMC in 240 mL of orange drink taken with meals
Number of subjects: 51
Study: 9196770

Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine/dapsone)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 8266770

Group type: EXPERIMENTAL
Intervention: Octreotide (3 x 100 micrograms per day sc.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2859136

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg) + Ethanol (800 to 950 mg/L)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo + Ethanol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Triazolam + Orange Juice
Number of subjects: 6
Study: 3070032

Group type: EXPERIMENTAL
Intervention: Verapamil (doses of 40 to 120 mg, twice daily for six weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 10
Study: 29670295

Group type: EXPERIMENTAL
Intervention: Longest tertile of telomere length
Number of subjects: 2022
Study: 28243132

Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT-tablet in addition to allergy pharmacotherapy
Number of subjects: 992

Group type: COMPARATOR
Intervention: Placebo plus allergy pharmacotherapy
Number of subjects: 992
Study: 26188211

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 8561

Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 8561
Study: 23924555

Group type: EXPERIMENTAL
Intervention: 5 Strain Dophilus
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hylak
Number of subjects: 14
Study: 20298994

Group type: EXPERIMENTAL
Intervention: 80-mg atorvastatin
Number of subjects: 171

Group type: COMPARATOR
Intervention: 10-mg atorvastatin
Number of subjects: 171
Study: 18206309

Group type: EXPERIMENTAL
Intervention: Advice provided by health care practitioners (HCPs) for a vignette patient with non-specific low back pain (NSLBP)
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Work advice related to Pain Attitudes and Beliefs Scale (PABS.PT) scores
Number of subjects: 1022
Study: 16715326

Group type: EXPERIMENTAL
Intervention: Constant flow insufflation of oxygen (CFIO) at a flow rate of 15 l/min
Number of subjects: 341

Group type: COMPARATOR
Intervention: Standard endotracheal intubation and mechanical ventilation (MV)
Number of subjects: 341
Study: 14507420

Group type: EXPERIMENTAL
Intervention: Education package applied to general practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: True endpoint data
Number of subjects: 0
Study: 11115207

Group type: EXPERIMENTAL
Intervention: Stepped collaborative care depression intervention
Number of subjects: 228

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 228
Study: 9109608

Group type: EXPERIMENTAL
Intervention: Dietary fiber (3, 4, or 7% of diet dry matter)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Total dietary fiber (TDF) and neutral detergent fiber (NDF)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Empirical formula for predicting ME content
Number of subjects: 17
Study: 8238158

Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 55

Group type: COMPARATOR
Intervention: No oral tocolytic (Control)
Number of subjects: 55
Study: 2930998

Group type: EXPERIMENTAL
Intervention: Zimeldine, 100 mg b.i.d.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Maprotiline, 75 mg b.i.d.
Number of subjects: 75
Study: 30837446

Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL) prior to high fidelity simulation training (HFS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High fidelity simulation training (HFS) prior to problem-based learning (PBL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both methods (PBL prior to HFS and HFS prior to PBL)
Number of subjects: 26
Study: 29629438

Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet-rich fibrin (L-PRF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (regular blood clot)
Number of subjects: 30
Study: 27497358

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metal drug-eluting stent (DES)
Number of subjects: 60
Study: 25637563

Group type: EXPERIMENTAL
Intervention: Dual/triple-chamber ICDs
Number of subjects: 2790

Group type: EXPERIMENTAL
Intervention: Single-chamber ICDs
Number of subjects: 2790
Study: 22927662

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 153

Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 153
Study: 21062484

Group type: EXPERIMENTAL
Intervention: VO2max estimated using the 2-km UKK walk test
Number of subjects: 427
Study: 17696215

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted surgery with BMI considered
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted surgery without considering BMI
Number of subjects: 488
Study: 17409843

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Carboplatin (CAR)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Cisplatin (CIS)
Number of subjects: 81
Study: 14609832

Group type: EXPERIMENTAL
Intervention: Next Day Review (NDR)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Same Day Discharge (SDD)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Both groups (SDD and NDR)
Number of subjects: 362
Study: 10672147

Group type: EXPERIMENTAL
Intervention: Two Striper MFS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sof-Lex XT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Enhance Composite Finishing and Polishing System
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Shofu Composite Finishing Kit
Number of subjects: 80
Study: 9094272

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 201
Study: 8237933

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg bid
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Clarithromycin 1000 mg bid
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg qid
Number of subjects: 37
Study: 3535491

Group type: EXPERIMENTAL
Intervention: Clotrimazole 10 mg troches, three times per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31945779

Group type: EXPERIMENTAL
Intervention: Exposure to environmental tobacco smoke (ETS) and high-perceived work stress
Number of subjects: 11875

Group type: EXPERIMENTAL
Intervention: Non-obese and non-smoking groups
Number of subjects: 11875
Study: 29799810

Group type: EXPERIMENTAL
Intervention: Polyacrylate polymer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Polyvinylpyrrolidone (PVP) polymer
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo product
Number of subjects: 32
Study: 26940678

Group type: EXPERIMENTAL
Intervention: Transition nurse program during hospital stay, on discharge day, and for 4 weeks after discharge.
Number of subjects: 630
Study: 26333529

Group type: EXPERIMENTAL
Intervention: Serelaxin treatment
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1161
Study: 23594784

Group type: EXPERIMENTAL
Intervention: 5,000 ppm fluoridated toothpaste
Number of subjects: 176

Group type: COMPARATOR
Intervention: 1,450 ppm fluoridated toothpaste
Number of subjects: 176
Study: 20358155

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily for eight weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg once daily for eight weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination of enalapril 10 mg and losartan 50 mg daily for eight weeks
Number of subjects: 34
Study: 17970793

Group type: EXPERIMENTAL
Intervention: Plasma volume expansion
Number of subjects: 172

Group type: COMPARATOR
Intervention: No plasma volume expansion (Control)
Number of subjects: 172
Study: 15911935

Group type: EXPERIMENTAL
Intervention: Modular psychotherapeutic intervention for anxiety
Number of subjects: 2

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2